Evidence map›Paper›PMID 38873603›Full record

ArticleFrontiers in immunology2024

Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function.

Abdullah Degirmencay, Sharyn Thomas, Angelika Holler, Samuel Burgess, Emma C Morris, Hans J Stauss

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Focusing on CD8Journal of experimental & clinical cancer research : CR · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdullah DegirmencayInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.
Sharyn ThomasInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.
Angelika HollerInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.
Samuel BurgessInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.
Emma C MorrisInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.
Hans J StaussInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College London, Pears Building, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression levels of TCRs on the surface of human T cells define the avidity of TCR-HLA/peptide interactions. In this study, we have explored which components of the TCR-CD3 complex are involved in determining the surface expression levels of TCRs in primary human T cells. The results show that there is a surplus of endogenous TCR α/β chains that can be mobilised by providing T cells with additional CD3γ,δ,ε,ζ chains, which leads to a 5-fold increase in TCR α/β surface expression. The analysis of individual CD3 chains revealed that provision of additional ζ chain alone was sufficient to achieve a 3-fold increase in endogenous TCR expression. Similarly, CD3ζ also limits the expression levels of exogenous TCRs transduced into primary human T cells. Interestingly, transduction with TCR plus CD3ζ not only increased surface expression of the introduced TCR, but it also reduced mispairing with endogenous TCR chains, resulting in improved antigen-specific function. TCR reconstitution experiments in HEK293T cells that do not express endogenous TCR or CD3 showed that TCRα/β and all four CD3 chains were required for optimal surface expression, while in the absence of CD3ζ the TCR expression was reduced by 50%. Together, the data show that CD3ζ is a key regulator of TCR expression levels in human T cells, and that gene transfer of exogenous TCR plus CD3ζ improved TCR surface expression, reduced TCR mispairing and increased antigen-specific function.

Indexed as

CD3 ComplexReceptors, Antigen, T-CellT-LymphocytesHEK293 CellsHumansLymphocyte ActivationReceptor-CD3 Complex, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-betaCD3 antigen, zeta chainCD3 ComplexReceptor-CD3 Complex, Antigen, T-CellReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-betaCD3-zetaT cell functionTCR mispairingTCR (T-cell receptor)TCR-T therapy

Identifiers

PMID38873603
PMCPMC11169823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.